



(51) International Patent Classification:

A61K 47/48 (2006.01) A61P 35/00 (2006.01)
C07D 309/32 (2006.01)

(21) International Application Number:

PCT/EP2014/061392

(22) International Filing Date:

2 June 2014 (02.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1309807.4 31 May 2013 (31.05.2013) GB

(71) Applicant: PHARMA MAR, S.A. [ES/ES]; Poligono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, E-28770 Madrid (ES).

(72) Inventors: CUEVAS MARCHANTE, Carmen; Pharma Mar S.A., Avda. de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo, E-28770 Madrid (ES). DOMÍNGUEZ CORREA, Juan Manuel; Pharma Mar S.A., Avda. de los

Reyes 1, P.I. La Mina-Norte, Colmenar Viejo, E-28770 Madrid (ES). FRANCESCH SOLLOSO, Andrés; Pharma Mar S.A., Avda. de los Reyes 1, P.I. La Mina-Norte, Colmenar Viejo, E-28770 Madrid (ES). GARRANZO GARCÍA-IBARROLA, María; Pharma Mar S.A., Avda. de los Reyes 1, P.I. La Mina-Norte, Colmenar Viejo, E-28770 Madrid (ES). MUNOZ ALONSO, María José; Pharma Mar S.A., Avda. de los Reyes 1, P.I. La Mina-Norte, Colmenar Viejo, E-28770 Madrid (ES). SÁNCHEZ MADRID, Francisco; Servicio de Inmunología, Hospital Universitario de la Princesa, c/ Diego de Leon, 62, E-28006 Madrid (ES). ZAPATA HERNÁNDEZ, Juan Manuel; Instituto de Investigaciones Bio-medicas "Alberto Sols" (IIBM), C/Arturo Duperier 4, E-28029 Madrid (ES). GARCÍA ARROYO, Alicia; Centro Nacional de Investigaciones Cardiovasculares, C/ Melchor Fernández Almagro, 3, E-28029 Madrid (ES). URSA PECHARROMÁN, María Ángeles; Servicio de Inmunología, Hospital Universitario de la Princesa, C/ Diego de Leon, 62, E-28006 Madrid (ES).

[Continued on next page]

(54) Title: ANTIBODY DRUG CONJUGATES





Figure 10



Statistical significance (student's t test): *** p < 0.001

(57) Abstract: Drug conjugates of formula [D-(X)_b-(AA)_w-(L)-J_n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R₁, R₂ and R₃ is H, OR_a, OCOR_a, OCO-OR_a, alkyl, alkenyl, alkynyl, etc.; R₃' is, COR_a, COOR_a, CONR_aR_b, etc; each of R₄ to R₁₀ and R₁₂ is alkyl, alkenyl or alkynyl; R₁₁ is H, COR_a, COOR_a, alkyl, alkenyl or alkynyl, or R₁₁ and R₁₂+N+C atoms to which they are attached may form a heterocyclic group; each of R₁₃ and R₁₄ is H, COR_a, COOR_a, alkyl, alkenyl or alkynyl; each R_a and R_b is H, alkyl, alkenyl, alkynyl, etc.; each dotted line represents an optional additional bond; X is an extending group; AA is an amino acid unit; L is a linker group; w is 0 to 12; b is 0 or 1; A bis a moiety comprising at least one antigen binding site, and n is the ratio of the group [D-(X)_b-(AA)_w-(L)-] to the moiety comprising at least one antigen binding site and is in the range from 1 to 20, are useful in the treatment of cancer.



(74) **Agent:** ANDREWS, Timothy; Marks & Clerk LLP, 62-68 Hills Road, Cambridge Cambridgeshire CB2 1LA (GB).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))